Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 5, 1997

View Archived Issues

Biomatrix: Q3 1997 highlights

Atrix: Q3 1997 highlights

The Liposome Company: Q3 1997 highlights

Sugen: Q3 1997 highlights

Bio-Technology General: Q3 1997 highlights

Matrix Pharmaceutical: Q3 1997 highlights

Neurobiological Technologies: Q1 1998 highlights

Sequana and Parke-Davis collaborate on drug discovery for CNS

Teijin licenses new thrombolytic from Schering AG

Peptides for autoimmune/inflammatory diseases linked to MHC molecules

Potent new fluoroquinolones described by Bayer

Novo Nordisk reports improved human insulin derivatives

Genetics Institute discloses new chemokine and its production

Lefradafiban: oral prodrug for profound and sustained inhibition of platelet aggregation

MCI-186: Mitsubishi Chemical's new candidate for acute stroke

New glycine-site NMDA partial agonist from ADIR

KGF fragments from Chiron display wound-healing activity

MMP inhibitors reported by ProScript

Zaprinast potentiates beneficial effects of inhaled NO in hypoxic pulmonary hypertension

New camptothecin analogues synthesized at U of Michigan

New alpha2-adrenoceptor agonists from Synaptic

Antihypertensive effects reported for kallikrein gene therapy

Labeling changes for Rezulin; FDA and manufacturer recommend liver function tests

New avenue opened for the treatment of congestive heart failure

New technology for BPH enters clinical trials in U.S.

Karo Bio/Merck & Co. form strategic alliance related to ER receptors

Theratechnologies and Chiron join forces against AIDS

NPS and SmithKline Beecham extend osteoporosis agreement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...